NouBio Inc

NouBio Inc is at the forefront of biotechnology research, dedicated to unlocking cell-based human longevity, biocomputers, and biomanufacturing. With a focus on bio-intelligent manufacturing of animal serum replacements and artificial intelligence-driven biocomputer deep technologies, NouBio is committed to reducing the costs of cell-based biomanufacturing by 95% while scaling the production of novel cell-based human longevity applications.

NouBio's deep technologies are designed to scale production across multiple cell-based human longevity and biomanufacturing industries, including cell therapies, cell vaccines, human tissue creation, cell-based blood, drug discovery/development, regenerative medicine, cell-based foods, cell-based materials, defense, biosecurity, and synthetic biology. NouBio is headquartered in Los Angeles, US, with an additional location in Maliebaan, Utrecht, NL. The company's first beta product, NouSerum, launched in 2024 and serves as a full Fetal Bovine Serum (FBS) replacement that reduces production costs by 50-95% while maintaining the same performance as FBS.

NouBio Inc is poised to revolutionize the biotechnology landscape with its innovative products and technologies. Future products include cost-effective, bio-degradable microcarriers, an artificial intelligence-driven robotic cellular biocomputer, and AI-driven formulas for enhanced cell-based products. NouBio is committed to driving advancements in the field of biotechnology. We invite the manager of NouBio Inc to create a customized and exclusive company showcase and product listing on our platform to further highlight their achievements and capabilities.